. 2021 Dec 2;101(2):297–307. doi: 10.1007/s00277-021-04712-8

Table 2.

Imatinib regimens and monitoring after treatment

Case	Imatinib dosage at diagnosis	Imatinib dosage at follow-up	CCR (months from imatinib)	CMR (months from imatinib)	Relapse	Last follow-up (months after imatinib)
1	100 mg	200 mg	+ 24	+ 24	No	+ 30^a
2	100 mg	100 mg	+ 4	+ 18	No	+ 30^a
3	400 mg	200 mg	+ 1	+ 25	No	+ 222^a
4	100 mg	100 mg	+ 9	+ 9	No	+ 61^a
5	n.a	n.a	+ 11	n.a	n.a	+ 33*
6	100 mg	200 mg	+ 24	n.a	No	+ 155*
7	100 mg	200 mg	+ 8	+ 32	No	+ 109^a
8	100 mg	200 mg	+ 40^§	+ 40^§	No	+ 42^a
9	400 mg	100 mg	+ 12	+ 44	No	+ 129^†
11	100 mg	200 mg	+ 12	No	No	+ 72^a
12	n.a	n.a	Maintained after CHT	Maintained after CHT	B-ALL	+ 11^†
13	400 mg	400 mg	+ 4	No	No	+ 9^†
14	400 mg	400 mg	+ 7	+ 10^#	AML	+ 36^†

CCR complete cytogenetic remission, CMR complete molecular remission, CHT chemotherapy, B-ALL B cell acute lymphoblastic leukemia, n.a. not available

^aAlive

^§First evaluation after treatment

^#Obtained after 8 months of imatinib therapy followed by 2 months of induction chemotherapy

^†Death

*Lost at follow up